Furthermore, given the functional importance of NAT10 in multiple myeloma as well as osteoporosis, targeting NAT10 signaling through selective promoters may be a promising therapeutic strategy for the treatment of osteosarcoma, particularly in patients with high NAT10 levels. The gene discussed is NAT10; the disease is plasma cell myeloma.